Alnylam Initiates Phase I Trial of Second-Gen TTR Amyloidosis Drug
March 22, 2012
Alnylam Initiates Phase I Trial of Second-Gen TTR Amyloidosis Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 7, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to UNC, Alnylam, FSU, and More
February 7, 2013 / Gene Silencing News - Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 8, 2012 / Gene Silencing News - Alnylam Launches Phase II Trial of Second-Generation Amyloidosis Drug
June 7, 2012 / Gene Silencing News - Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News